Acorda Therapeutics (NASDAQ:ACOR – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Risk & Volatility Acorda Therapeutics has a beta of […]
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Profitability This table compares Acorda Therapeutics and Adaptimmune Therapeutics’ […]
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) have been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […]
Bryan, Garnier & Co started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued a buy rating and a $3.60 price target on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Guggenheim upgraded shares […]
Equities research analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research note issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. ADAP has been the topic of a number of other reports. Guggenheim raised shares of Adaptimmune Therapeutics from a “neutral” rating […]